Both these vaccines were used in India during the Corona period. Now, after four years of the Corona period, the effect of these two vaccines is becoming visible. Covishield is reported to cause blood clotting problems, while Covaxin is reported to have some side effects including respiratory problems.
Taking Covaxin can cause death after 2 years?
In some videos viral on social media, it is being claimed that taking Covaxin made in India can lead to death after 2 years. Obviously this is the same vaccine which was administered to protect many people from Corona. An ex-user has shared a post claiming that Covaxin Covid vaccine has caused the deaths of crores of people across India.
Is Covaxin causing death?
The effect of the vaccine is coming after two years, crores of lives have been lost.#covishield #Covaxin #heartattack #IndiaAlliance #ArrestRendraModi #LokSabhaElections2024 #covishield #Covaxin pic.twitter.com/TrcZP0XxXY
– Mazhar Khan (@mazharhan_SPO) 2 May 2024
what is the reality
It is being claimed on social media that taking Covaxin, the Covid-19 vaccine developed by Bharat Biotech, can lead to death after two years. This claim is completely false and misleading. According to the available data, there is no strong evidence of increased risk of heart attack or death after two years of taking Covaxin. All vaccines, including Covaxin, undergo rigorous testing on their safety and effectiveness before they are approved. Also, even after getting approval, their monitoring continues.
Covaxin has some side effects
It is true that some problems may occur after taking the vaccine. But, these problems are usually seen soon after vaccination, and it is extremely rare to have serious long-term side effects. WHO had approved Covaxin for emergency use after a thorough analysis of risks and benefits. Heart attacks and other cardiovascular problems can occur for many reasons, including pre-existing health problems, lifestyle, and genetics. Such events occurring two years after receiving the vaccine are unlikely to be directly related to the vaccine.
A large clinical trial of Covaxin was conducted
In June 2020, India's Ministry of Health and Family Welfare gave permission to begin Phase I and II human trials for Covaxin after preliminary studies. These studies showed that it is safe and can produce strong immune responses in animals. Bharat Biotech conducted Phase I and Phase II trials involving around 1,000 people.
These trials yielded good safety and immunogenicity results and were published in international scientific journals. Its third phase trial was conducted in November 2020 in which 26,000 people from India were included. The vaccine was approved only after seeing its safety and effectiveness.
Disclaimer: This article is for general information only. It cannot in any way be a substitute for any medicine or treatment. Always consult your doctor for further details.
, ArticlesDiv.innerHTML += ArticleHTML; , } //Initially fetch and render feeds FetchAndRenderFeeds();
